Divozilimab

Summary

Divozilimab (CHEMBL5314981) is a phase-3 clinical-stage antibody (ATC L04AG15) targeting MS4A1; indicated across 2 conditions including systemic sclerosis and neuromyelitis optica.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• ATC class: L04AG15
• Targets: 1 (MS4A1)
• Indications: 2 conditions
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314981
Name	Divozilimab
Type	Antibody
Max phase	3
ATC	L04AG15

Also known as: Divozilimab, DIVOZILIMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
MS4A1	CD20 (membrane-spanning 4-domains, subfamily A, member 1)			0%	P11836

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): MS4A1.

Dominant GO biological processes

GO term	Targets
store-operated calcium entry	1
humoral immune response	1
cell surface receptor signaling pathway	1
response to bacterium	1
B cell differentiation	1
B cell proliferation	1
B cell activation	1
B cell receptor signaling pathway	1
protein tetramerization	1
calcium ion import into cytosol	1
positive regulation of calcium ion import across plasma membrane	1

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
systemic sclerosis	3	MONDO:0005100	EFO:0000717
neuromyelitis optica	3	MONDO:0019100	EFO:0004256

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	3
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05726630	PHASE3	ACTIVE_NOT_RECRUITING	Clinical Study of Divozilimab in Patients With Systemic Scleroderma
NCT05730699	PHASE3	ACTIVE_NOT_RECRUITING	Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)
NCT06987851	PHASE3	COMPLETED	An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD
NCT07136389	PHASE1	RECRUITING	Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).